CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...